Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory W Roloff

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Haematologica|January 29, 2026
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitorsJoseph M Cannova, Muriel R Battaglia, Gregory W Roloff, et al.
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances|August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Haematologica|January 29, 2026
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitorsJoseph M Cannova, Muriel R Battaglia, Gregory W Roloff, et al.
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances|June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLTamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances|August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Pageof 4